EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy and safety of risankizumab in paediatric patients with psoriasis in the OptIMMize-1 phase III study

Nina Magnolo, Wine Lee Lara, Adam Reich, Irene Lara-Corrales, Akimichi Morita iD, Michael Bukhalo, Asunción Vicente, Toni Anschutz, Rosie D Lyles, Tshepiso Madihlaba, Kristina Unnebrink, Doug Ashley und 3 weitere

British Journal of Dermatology · 26.09.2026

DOI: 10.1093/bjd/ljag403 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Dermatology, online erschienen am 26.09.2026. Verfasst von Nina Magnolo und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University Hospital Münster, Münster, Germany. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Treatment options for paediatric patients with psoriasis are limited, and additional, more advanced therapies are needed. Risankizumab is an interleukin-23 inhibitor approved to treat moderate-to-severe psoriasis in adults.

Objectives

To evaluate efficacy and safety of risankizumab through 52 weeks in paediatric patients with moderate-to-severe psoriasis.

Methods

OptIMMize-1 (Clinical Trial Registration NCT04435600) was a phase III, multicentre, four-part study. Parts 1, 3 and 4 were 52-week, open-label studies. Part 2 consisted of a 16-week initial treatment period (Period A; 2 : 1 risankizumab: ustekinumab randomization), followed by up to 36-week randomized treatment or withdrawal period (Period B) for patients whose disease responded to risankizumab, with a potential 16-week retreatment period (Period C) for patients who experienced a disease flare. Patients whose disease did not respond to risankizumab and patients randomized to ustekinumab in Period A received risankizumab during Period B. Key outcomes were a static Physician’s Global Assessment (sPGA) score of clear or almost clear (sPGA 0/1), sPGA 0 or 1 with ≥ 2-grade improvement (sPGA 0/1 + ≥ 2GI) or achievement of ≥ 75%, ≥ 90% or 100% improvement in Psoriasis Area and Severity Index (PASI 75/90/100). The study also assessed itch severity, quality of life and safety.

Results

A total of 137 patients enrolled. In Part 2 (risankizumab, n = 54; ustekinumab, n = 28), week 16 response rates were similar: sPGA 0/1 was 80% (n = 43/54) for risankizumab and 75% (n = 21/28) for ustekinumab; sPGA 0/1 + ≥ 2GI rates were 69% (n = 37/54) vs. 68% (n = 19/28); PASI 75 rates were 85% (n = 46/54) vs. 86% (n = 24/28); and PASI 90 rates were 65% (n = 35/54) vs. 61% (n = 17/28). PASI 100 responses were higher with risankizumab (41%, n = 22/54) than with ustekinumab (18%, n = 5/28). In Part 4 (n = 30), week 16 rates were sPGA 0/1: 90% (n = 27/30), sPGA 0/1 + ≥ 2GI: 83% (n = 25/30), PASI 75: 87% (n = 26/30), PASI 90: 77% (n = 23/30) and PASI 100: 43% (n = 13/30); week 52 responses were maintained or improved. Skin clearance outcomes in Parts 1 and 3 were consistent with those observed with continuous risankizumab treatment in Parts 2 and 4. Improvements in itch and quality of life (assessed in Part 2 only) were observed at weeks 16 and 52. Risankizumab safety profiles were consistent with those observed in prior adult psoriasis studies.

Conclusions

Risankizumab was well tolerated in paediatric patients, with marked improvements in skin clearance, itching and quality of life. Efficacy was maintained or improved at week 52, supporting risankizumab use for moderate-to-severe psoriasis in this population.

Autor:innen und Institutionen

  • Department of Dermatology, University Hospital Münster, Münster, Germany.
  • Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina, Charleston, SC, USA.
  • Department of Dermatology, Faculty of Medicine, Medical College, University of Rzeszów, Rzeszów, Poland.
  • Department of Paediatrics, Division of Dermatology, The Hospital for Sick Children, Toronto, ON, Canada.
  • Department of Geriatric and Environmental Dermatology, Nagoya City University, Nagoya, Japan.
  • Arlington Dermatology, Rolling Meadows, IL, USA.

ORCID-Profile: Akimichi Morita

Förderung

  • AbbVie

Zitieren

APA

Magnolo, N., Lara, W. L., Reich, A., Lara-Corrales, I., Morita, A., Bukhalo, M., Vicente, A., Anschutz, T., Lyles, R. D., Madihlaba, T., Unnebrink, K., Ashley, D., Sharma, D., D'Cunha, R., & Paller, A. S. (2026). Efficacy and safety of risankizumab in paediatric patients with psoriasis in the OptIMMize-1 phase III study. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljag403

Vancouver

Magnolo N, Lara WL, Reich A, Lara-Corrales I, Morita A, Bukhalo M, et al. Efficacy and safety of risankizumab in paediatric patients with psoriasis in the OptIMMize-1 phase III study. British Journal of Dermatology. 2026. doi:10.1093/bjd/ljag403

BibTeX
@article{Magnolo2026,
  author = {Magnolo, Nina and Lara, Wine Lee and Reich, Adam and Lara-Corrales, Irene and Morita, Akimichi and Bukhalo, Michael and Vicente, Asunción and Anschutz, Toni and Lyles, Rosie D and Madihlaba, Tshepiso and Unnebrink, Kristina and Ashley, Doug and Sharma, Dolly and D'Cunha, Ronilda and Paller, Amy S},
  title = {Efficacy and safety of risankizumab in paediatric patients with psoriasis in the OptIMMize-1 phase III study},
  journal = {British Journal of Dermatology},
  year = {2026},
  doi = {10.1093/bjd/ljag403}
}
Kostenlos starten →